1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Masimo Corp

Masimo is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Masimo's mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.4 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,5 improve CCHD screening in newborns,6 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.7-10 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,11 and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2020-21 U.S. News and World Report Best Hospitals Honor Roll.12 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient's physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo's family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView :60™, and Masimo SafetyNet™.
Joe Kiani

52 Discovery
Irvine, California 92618-3105
Phone: 19492977000


Masimo Founder and CEO Joe Kiani to Speak on AI at Global Patient Safety Summit in Chile
Apr 16, 2024 12:00pm

Masimo (NASDAQ: MASI) today announced that its Founder and CEO, Joe Kiani, will be a featured speaker tomorrow, April 17, at the 6th Global Ministerial Summit on Patient Safety. Kiani’s speech, “Empowering Patient Safety Through AI,” will discuss how artificial intelligence-based technologies, by analyzing both historical and immediate data, can help clinicians prevent errors of omission, Jetzt den vollständigen Artikel lesen

Stifel upgrades Masimo to buy, sees room for share price appreciation
Apr 15, 2024 18:36pm

No summary available.

Source:Seeking Alpha
What''s Driving Masimo Corp''s Surprising 17% Stock Rally?
Apr 15, 2024 15:12pm

What''s Driving Masimo Corp''s Surprising 17% Stock Rally?

Apple Asks Appeals Court to Reverse Smartwatch Import Ban as Masimo Patent Battle Continues
Apr 09, 2024 20:23pm

The tech giant said the decision to ban the watches were made relying on Masimo patents that were “purely hypothetical” when filing the complaint in 2021.

Apple Urges US Appeals Court to Overturn ITC''s Apple Watch Import Ban Amidst Masimo Dispute
Apr 06, 2024 08:09am

Apple has asked a US appeals court to reverse a decision by the US International Trade Commission''s (ITC) decision to ban the imports of some Apple Watch models in the US amid the ongoing dispute with Masimo. The company has removed pulse oximetry features from Apple Watch Series 9 and Watch Ultra 2 models sold during the appeal period, which could last for at least a year.

Source:Gadgets 360
Tim Cook-Led Tech Giant Appeals To US Court For Overturning Import Ban On Its Apple Watches
Apr 06, 2024 07:25am

Apple Inc. (NASDAQ: AAPL ) has appealed to a U.S. appeals court to reverse a ban on the import of certain Apple Watches . The ban was imposed following a patent dispute with medical-monitoring technology company Masimo Corporation (NASDAQ: MASI ). What Happened : On Friday, Apple requested the U.S. Court of Appeals for the Federal Circuit to overturn the U.S. International Trade Commission’s or ITC decision to ban the import of specific Apple Watches, reported Reuters. Cupertino, California-based tech giant informed the Federal Circuit that the prohibition could not be upheld because the Masimo wearable, protected by the patents, was merely theoretical at the time of its ITC complaint in 2021. Additionally, the technology company contended that Masimo’s patents lacked validity and that its watches did not violate them. See Also: Apple Unveiling AI Strategy At WWDC 2024 Will Be A ‘Watershed Moment,’ Says Wedbush’s Dan Ives: Stock Could Go ‘Massively Higher’ To $250 Masimo, based … Full story available on Benzinga.

Here’s Apple’s 916-page appeal over the Apple Watch ban
Apr 05, 2024 23:05pm

Apple’s not too happy that Masimo’s W1 watch didn’t exist when Masimo filed its complaint. | Photo by Amelia Holowaty Krales / The Verge There was no question that Apple would appeal when the International Trade Commission banned Apple Watch Series 9 and Ultra 2 sales last year. Well, if you’ve got some time, you can now read all 916 pages of Apple’s appeal to the Federal Circuit. A quick recap: the Apple Watch ban centers around whether Apple infringed upon medical device-maker Masimo’s pulse oximetry patents. The ITC sided with Masimo, concluding that Apple had infringed their patents, and that the infringement was harming domestic industry. The ITC is an agency similar to a court that often deals with imported “articles” that may or may not violate intellectual property law. The word “article” matters more than you’d think, since the statute that created the ITC… Continue reading…

Source:The Verge
Masimo Responds to Politan Capital’s Nomination of Director Candidates and Refutes Politan’s False Claims
Apr 01, 2024 12:00pm

Masimo (NASDAQ: MASI) today confirmed that Politan Capital Management LP (“Politan”) has provided notice of its intent to nominate two candidates to stand for election to the Masimo Board of Directors at the company’s 2024 Annual Meeting. While Masimo respects and values the input and ideas of all its stockholders and respects their right to nominate and elect the directors of their choice, Jetzt den vollständigen Artikel lesen

Masimo CEO on potential split, proxy battle and spinning off consumer business
Mar 25, 2024 20:46pm

Joe Kiani, Masimo CEO, joins ''Closing Bell: Overtime'' to discuss the company spinning off its consumer business.

Masimo considering JV for consumer division: WSJ
Mar 25, 2024 19:21pm

No summary available.

Source:Seeking Alpha